Ford Motor Company vs uniQure N.V. Ordinary Shares — how do they compare? Ford Motor Company trades at $12.13 (market cap $48.05B), while uniQure N.V. Ordinary Shares trades at $20.71 (market cap $1.45B). The key difference: Ford Motor Company is far larger — about 33.1× uniQure N.V. Ordinary Shares's market cap, and Ford Motor Company pays a 4.98% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ford Motor Company for 105 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| F | QURE | |
|---|---|---|
Market Cap | $48.05B | $1.45B |
Volume | 32,239,630 | 3,323,243 |
Sector | Consumer Cyclical | Health |
52-Week High | $17.44 | $70.59 |
52-Week Low | $11.21 | $9.03 |
Typical Hold Time | 105 Days | 0 Days |
Enterprise Value | $180.01B | $707.46M |
Dividend Yield | 4.98% | — |
Signals from Pluang's Aura AI — not financial advice
Ford Motor Company (F) trades at $12.10, up 0.83% with bearish technical indicators but mixed fundamentals. The stock shows negative profitability with a -3.93% net margin and -18.31% ROE, though recent quarters saw earnings beats. Operating cash flow remains strong at $21.28B (2025), but sales declined 6.6% in Q3 2026 amid supplier disruptions and model phase-outs. Analyst consensus is mixed with 38.3% buy ratings and a $15.79 price target, suggesting 30% upside potential from current levels.
Ford faces near-term headwinds from production challenges and competitive pressures, but valuation appears attractive with P/E of 11.21 and P/S of 0.26. The company's shift toward hybrids and commercial vehicle strength provides long-term opportunities, though execution risks and debt levels warrant caution. Current price near recent lows offers potential entry for value investors comfortable with automotive sector volatility.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Ford Motor Company designs, manufactures, and services cars and trucks. The Company also provides vehicle-related financing, leasing, and insurance through its subsidiary.
Read more on F →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →